145 related articles for article (PubMed ID: 37929602)
1. Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13 970 Contemporary High-Risk Patients With Statin Intolerance.
Ridker PM; Lei L; Louie MJ; Haddad T; Nicholls SJ; Lincoff AM; Libby P; Nissen SE;
Circulation; 2024 Jan; 149(1):28-35. PubMed ID: 37929602
[TBL] [Abstract][Full Text] [Related]
2. Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials.
Ridker PM; Bhatt DL; Pradhan AD; Glynn RJ; MacFadyen JG; Nissen SE;
Lancet; 2023 Apr; 401(10384):1293-1301. PubMed ID: 36893777
[TBL] [Abstract][Full Text] [Related]
3. Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial.
Nicholls SJ; Nelson AJ; Lincoff AM; Brennan D; Ray KK; Cho L; Menon V; Li N; Bloedon L; Nissen SE
JAMA Cardiol; 2024 Mar; 9(3):245-253. PubMed ID: 38231501
[TBL] [Abstract][Full Text] [Related]
4. Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammation Reduction Trial.
Ridker PM; MacFadyen JG; Glynn RJ; Bradwin G; Hasan AA; Rifai N
Eur Heart J; 2020 Aug; 41(31):2952-2961. PubMed ID: 32221587
[TBL] [Abstract][Full Text] [Related]
5. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.
Nissen SE; Lincoff AM; Brennan D; Ray KK; Mason D; Kastelein JJP; Thompson PD; Libby P; Cho L; Plutzky J; Bays HE; Moriarty PM; Menon V; Grobbee DE; Louie MJ; Chen CF; Li N; Bloedon L; Robinson P; Horner M; Sasiela WJ; McCluskey J; Davey D; Fajardo-Campos P; Petrovic P; Fedacko J; Zmuda W; Lukyanov Y; Nicholls SJ;
N Engl J Med; 2023 Apr; 388(15):1353-1364. PubMed ID: 36876740
[TBL] [Abstract][Full Text] [Related]
6. Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients.
Nissen SE; Menon V; Nicholls SJ; Brennan D; Laffin L; Ridker P; Ray KK; Mason D; Kastelein JJP; Cho L; Libby P; Li N; Foody J; Louie MJ; Lincoff AM
JAMA; 2023 Jul; 330(2):131-140. PubMed ID: 37354546
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial.
Ray KK; Nicholls SJ; Li N; Louie MJ; Brennan D; Lincoff AM; Nissen SE;
Lancet Diabetes Endocrinol; 2024 Jan; 12(1):19-28. PubMed ID: 38061370
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory and Cholesterol Risk in the FOURIER Trial.
Bohula EA; Giugliano RP; Leiter LA; Verma S; Park JG; Sever PS; Lira Pineda A; Honarpour N; Wang H; Murphy SA; Keech A; Pedersen TR; Sabatine MS
Circulation; 2018 Jul; 138(2):131-140. PubMed ID: 29530884
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance.
Laufs U; Banach M; Mancini GBJ; Gaudet D; Bloedon LT; Sterling LR; Kelly S; Stroes ESG
J Am Heart Assoc; 2019 Apr; 8(7):e011662. PubMed ID: 30922146
[TBL] [Abstract][Full Text] [Related]
10. Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy.
Pradhan AD; Aday AW; Rose LM; Ridker PM
Circulation; 2018 Jul; 138(2):141-149. PubMed ID: 29716940
[TBL] [Abstract][Full Text] [Related]
11. Clinical Benefit of Bempedoic Acid in Randomized Clinical Trials.
Cordero A; Fernandez Olmo R; Santos-Gallego CG; Fácila L; Bonanad C; Castellano JM; Rodriguez-Mañero M; Seijas-Amigo J; González-Juanatey JR; Badimon JJ
Am J Cardiol; 2023 Oct; 205():321-324. PubMed ID: 37633067
[TBL] [Abstract][Full Text] [Related]
12. Rationale and design of the CLEAR-outcomes trial: Evaluating the effect of bempedoic acid on cardiovascular events in patients with statin intolerance.
Nicholls S; Lincoff AM; Bays HE; Cho L; Grobbee DE; Kastelein JJ; Libby P; Moriarty PM; Plutzky J; Ray KK; Thompson PD; Sasiela W; Mason D; McCluskey J; Davey D; Wolski K; Nissen SE
Am Heart J; 2021 May; 235():104-112. PubMed ID: 33470195
[TBL] [Abstract][Full Text] [Related]
13. Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia.
Banach M; Duell PB; Gotto AM; Laufs U; Leiter LA; Mancini GBJ; Ray KK; Flaim J; Ye Z; Catapano AL
JAMA Cardiol; 2020 Oct; 5(10):1124-1135. PubMed ID: 32609313
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study.
Ballantyne CM; Banach M; Mancini GBJ; Lepor NE; Hanselman JC; Zhao X; Leiter LA
Atherosclerosis; 2018 Oct; 277():195-203. PubMed ID: 29910030
[TBL] [Abstract][Full Text] [Related]
15. Effects of bempedoic acid on CRP, IL-6, fibrinogen and lipoprotein(a) in patients with residual inflammatory risk: A secondary analysis of the CLEAR harmony trial.
Ridker PM; Lei L; Ray KK; Ballantyne CM; Bradwin G; Rifai N
J Clin Lipidol; 2023; 17(2):297-302. PubMed ID: 36813656
[TBL] [Abstract][Full Text] [Related]
16. Bempedoic acid lowers high-sensitivity C-reactive protein and low-density lipoprotein cholesterol: Analysis of pooled data from four phase 3 clinical trials.
Stroes ESG; Bays HE; Banach M; Catapano AL; Duell PB; Laufs U; Mancini GBJ; Ray KK; Sasiela WJ; Zhang Y; Gotto AM
Atherosclerosis; 2023 May; 373():1-9. PubMed ID: 37075696
[TBL] [Abstract][Full Text] [Related]
17. Adenosine Triphosphate Citrate Lyase and Fatty Acid Synthesis Inhibition: A Narrative Review.
Duarte Lau F; Giugliano RP
JAMA Cardiol; 2023 Sep; 8(9):879-887. PubMed ID: 37585218
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.
Ray KK; Bays HE; Catapano AL; Lalwani ND; Bloedon LT; Sterling LR; Robinson PL; Ballantyne CM;
N Engl J Med; 2019 Mar; 380(11):1022-1032. PubMed ID: 30865796
[TBL] [Abstract][Full Text] [Related]
19. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.
Ballantyne CM; Laufs U; Ray KK; Leiter LA; Bays HE; Goldberg AC; Stroes ES; MacDougall D; Zhao X; Catapano AL
Eur J Prev Cardiol; 2020 Apr; 27(6):593-603. PubMed ID: 31357887
[TBL] [Abstract][Full Text] [Related]
20. Association of Initial and Serial C-Reactive Protein Levels With Adverse Cardiovascular Events and Death After Acute Coronary Syndrome: A Secondary Analysis of the VISTA-16 Trial.
Mani P; Puri R; Schwartz GG; Nissen SE; Shao M; Kastelein JJP; Menon V; Lincoff AM; Nicholls SJ
JAMA Cardiol; 2019 Apr; 4(4):314-320. PubMed ID: 30840024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
